Keyphrases
Diabetic Nephropathy
100%
Diabetic Kidney Disease
100%
Podocyte Injury
100%
Endothelin Signalling
100%
Endothelin Receptor Antagonist
80%
Endothelin-1 (ET-1)
60%
Clinical Practice
20%
Pathophysiology
20%
Heart Failure
20%
Diabetes Management
20%
Novel Therapeutics
20%
Proteinuria
20%
Podocyte
20%
Therapeutic Potential
20%
Nephroprotective Effect
20%
End-stage Kidney Disease
20%
Current Treatment
20%
Glomerular Filtration Barrier
20%
Safety Self-efficacy
20%
Emerging Therapeutics
20%
Glomerulosclerosis
20%
Endothelin Receptor
20%
Endothelin B Receptor
20%
Pathophysiological Roles
20%
Therapeutic Implications
20%
Sparsentan
20%
Mesangial Cell Proliferation
20%
Atrasentan
20%
Fluid Retention
20%
Medicine and Dentistry
Diabetic Nephropathy
100%
Podocyte
100%
Endothelin
100%
Endothelin Receptor Antagonist
40%
Endothelin 1
20%
Pathophysiology
10%
Receptor
10%
Diabetes
10%
Cell Proliferation
10%
Proteinuria
10%
End Stage Renal Disease
10%
Congestive Heart Failure
10%
Glomerulosclerosis
10%
Glomerular Filtration Barrier
10%
Atrasentan
10%
Sclerosis
10%
Fluid Retention
10%
Mesangial Cell
10%
Sparsentan
10%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetic Nephropathy
100%
Endothelin
100%
Endothelin Receptor Antagonist
40%
Endothelin 1
20%
Pathophysiology
10%
Receptor
10%
Proteinuria
10%
End Stage Renal Disease
10%
Congestive Heart Failure
10%
Glomerulosclerosis
10%
Sclerosis
10%
Sparsentan
10%
Atrasentan
10%